Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine

Cellular Immunology

Volumn 227, Issue 2, 2004, Pages 93-102

  Meijer, Sybren L ^a   Dols, Annemieke ^a   Hu, Hong Ming ^a,b   Chu, Yiwei ^a   Romero, Pedro ^c   Urba, Walter J ^a   Fox, Bernard A ^a,b  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

Author keywords

IFN ; IL 5; Immunotherapy; Melanoma; Renal cell carcinoma; Sentinel lymph node; Tetramer; Tumor vaccine; Tumor specific T cells

Indexed keywords

AUTOANTIGEN; L SELECTIN; PADGEM PROTEIN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BLOOD AUTOTRANSFUSION; CELL CULTURE; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; HUMAN; HUMAN CELL; LYMPH NODE; LYMPHATIC DRAINAGE; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TECHNIQUE; TUMOR CELL; VACCINATION;

CANCER VACCINES; CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-5; KIDNEY NEOPLASMS; L-SELECTIN; LYMPH NODES; MELANOMA; T-LYMPHOCYTES;

MURINAE;

EID: 2342551968     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellimm.2004.01.006     Document Type: Article

References (48)

1. Jung T.M., Gallatin W.M., Weissman I.L., Dailey M.O. Down-regulation of homing receptors after T cell activation. J. Immunol. 141:1988;4110
2. Mobley J.L., Dailey M.O. Regulation of adhesion molecule expression by CD8 T cells in vivo. I. Differential regulation of gp90MEL-14 (LECAM-1), Pgp-1, LFA-1, and VLA-4 alpha during the differentiation of cytotoxic T lymphocytes induced by allografts. J. Immunol. 148:1988;2348
3. Mobley J.L., Rigby S.M., Dailey M.O. Regulation of adhesion molecule expression by CD8 T cells in vivo. II. Expression of L-selectin (CD62L) by memory cytolytic T cells responding to minor histocompatibility antigens. J. Immunol. 153:1994;5443
4. Picker L.J., Treer J.R., Ferguson-Darnell B., Collins P.A., Buck D., Terstappen L.W. Control of lymphocyte recirculation in man. I. Differential regulation of the peripheral lymph node homing receptor L-selection on T cells during the virgin to memory cell transition. J. Immunol. 150:1993;1105
5. Tedder T.F., Matsuyama T., Rothstein D., Schlossman S.F., Morimoto C. Human antigen-specific memory T cells express the homing receptor (LAM-1) necessary for lymphocyte recirculation. Eur. J. Immunol. 20:1990;1351
6. Kagamu H., Touhalisky J., Plautz G., Krauss J., Shu S. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res. 56:1996;4338
7. Hu H.M., Urba W.J., Fox B.A. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J. Immunol. 161:1998;3033
8. Tsung K., Meko J.B., Peplinski G.R., Tsung Y.L., Norton J.A. IL-12 induces T helper 1-directed antitumor response. J. Immunol. 158:1997;3359
9. Barth R.J. Jr., Mule J.J., Spiess P.J., Rosenberg S.A. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J. Exp. Med. 173:1991;647
10. Shu S., Krinock R.A., Matsumura T., Sussman J.J., Fox B.A., Chang A.E., Terman D.S. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J. Immunol. 152:1994;1277
11. Zou J., Yamamoto N., Fujii T., Takenaka H., Kobayashi M., Herrmann S., Wolf S., Fujiwara H., Hamaoka T. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int. Immunol. 7:1995;1135
12. Aebersold P., Hyatt C., Johnson S., Hines K., Korcak L., Sanders M., Lotze M., Topalian S., Yang J., Rosenberg S.A. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J. Natl. Cancer Inst. 83:1991;932
13. Hayakawa K., Salmeron M.A., Parkinson D.R., Markowitz A.B., von Eschenbach A.C., Legha S.S., Balch C.M., Ross M.I., Augustus L.B., Itoh K. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC. J. Immunother. 10:1991;313
14. Ravaud A., Legrand E., Delaunay M.M., Bussieres E., Coulon V., Cany L., Huet S., Verdier D., Kind M., Chomy F., et al. A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma. Br. J. Cancer. 71:1995;331
15. Tamada K., Harada M., Okamoto T., Takenoyama M., Ito O., Matsuzaki G., Nomoto K. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2. Cancer Immunol. Immunother. 41:1995;339
16. Topalian S.L., Solomon D., Avis F.P., Chang A.E., Freerksen D.L., Linehan W.M., Lotze M.T., Robertson C.N., Seipp C.A., Simon P., et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 6:1988;839
17. Meijer S.L., Dols A., Urba W.J., Hu H.M., Smith I.J., Vetto J., Wood W., Doran T., Chu Y., Sayaharuban P., Alvord W.G., Fox B.A. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells. J. Immunother. 25:2002;359
18. Smith J.W. 2nd, Walker E.B., Fox B.A., Haley D., Wisner K.P., Doran T., Fisher B., Justice L., Wood W., Vetto J., Maecker H., Dols A., Meijer S., Hu H.M., Romero P., Alvord W.G., Urba W.J. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J. Clin. Oncol. 21:2003;1562
19. Inoue M., Plautz G.E., Shu S. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells. Cancer Res. 56:1996;4702
20. Fernandez-Cruz E., Gilman S.C., Feldman J.D. Immunotherapy of a chemically-induced sarcoma in rats: characterization of the effector T cell subset and nature of suppression. J. Immunol. 128:1982;1112
21. Yoshizawa H., Chang A.E., Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol. 147:1991;729
22. Chang A.E., Aruga A., Cameron M.J., Sondak V.K., Normolle D.P., Fox B.A., Shu S. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J. Clin. Oncol. 15:1997;796
23. Greenberg P.D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:1991;281
24. Rosenberg S.A., Terry W.D. Passive immunotherapy of cancer in animals and man. Adv. Cancer Res. 25:1977;323
25. Mitchison N.A. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J. Exp. Med. 102:1955;157
26. Shu S., Hunter J.T., Rapp H.J., Fonseca L.S. Mechanisms of immunologic eradication of a syngeneic guinea pig tumor. I. Quantitative analysis of adoptive immunity. J. Natl. Cancer Inst. 68:1982;673
27. Fox B.A., Spiess P.J., Kasid A., Puri R., Mule J.J., Weber J.S., Rosenberg S.A. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. J. Biol. Response Modif. 9:1990;499
28. Winter H., Hu H.M., Urba W.J., Fox B.A. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). J. Immunol. 163:1999;4462
29. Peng L., Krauss J.C., Plautz G.E., Mukai S., Shu S., Cohen P.A. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics. J. Immunol. 165:2000;7116
30. Winter H., Hu H.M., McClain K., Urba W.J., Fox B.A. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy. J. Immunol. 166:2001;7370
31. Seki N., Brooks A.D., Carter C.R., Back T.C., Parsoneault E.M., Smyth M.J., Wiltrout R.H., Sayers T.J. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J. Immunol. 168:2002;3484
32. Poehlein C.H., Hu H.M., Yamada J., Assmann I., Alvord W.G., Urba W.J., Fox B.A. TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells. J. Immunol. 170:2003;2004
33. Aruga A., Aruga E., Tanigawa K., Bishop D.K., Sondak V.K., Chang A.E. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J. Immunol. 159:1997;664
34. Dobrzanski M.J., Reome J.B., Dutton R.W. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases. J. Immunol. 162:1999;6671
35. Winter H., Hu H.M., Poehlein C.H., Huntzicker E., Osterholzer J.J., Bashy J., Lashley D., Lowe B., Yamada J., Alvord G., Urba W.J., Fox B.A. Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies. Immunology. 108:2003;409
36. Seder R.A., Paul W.E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu. Rev. Immunol. 12:1994;635
37. Dols A., Smith J.W. II, Meijer S.L., Fox B.A., Hu H.-M., Rosenheim W.E.S., Moudgil T., Doran T., Wood W., Seligman M., Alvord G., Schoof D., Urba W.J. Vaccination of women with metastatic breast cancer using a costimulatory gene (CD80)-modified HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Human Gene Ther. 14:2003;1117
38. Tatsumi T., Kierstead L.S., Ranieri E., Gesualdo L., Schena F.P., Finke J.H., Bukowski R.M., Mueller-Berghaus J., Kirkwood J.M., Kwok W.W., Storkus W.J. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J. Exp. Med. 196:2002;619
39. Yee C., Thompson J.A., Roche P., Byrd D.R., Lee P.P., Piepkorn M., Kenyon K., Davis M.M., Riddell S.R., Greenberg P.D. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J. Exp. Med. 192:2000;1637
40. Dudley M.E., Wunderlich J., Nishimura M.I., Yu D., Yang J.C., Topalian S.L., Schwartzentruber D.J., Hwu P., Marincola F.M., Sherry R., Leitman S.F., Rosenberg S.A. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24:2001;363
41. Dudley M.E., Wunderlich J.R., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R.M., Marincola F.M., Leitman S.F., Seipp C.A., Rogers-Freezer L., Morton K.E., Nahvi A., Mavroukakis S.A., White D.E., Rosenberg S.A. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25:2002;243
42. Hu H.M., Winter H., Urba W.J., Fox B.A. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy. J. Immunol. 165:2000;4246
43. Chang A.E., Li Q., Jiang G., Sayre D.M., Braun T.M., Redman B.G. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J. Clin. Oncol. 21:2003;884
44. Ribas A., Butterfield L.H., Glaspy J.A., Economou J.S. Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol. 21:2003;2415
45. Kanegane H., Kasahara Y., Niida Y., Yachie A., Sughii S., Takatsu K., Taniguchi N., Miyawaki T. Expression of L-selectin (CD62L) discriminates Th1- and Th2-like cytokine-producing memory CD4+ T cells. Immunology. 87:1996;186
46. Sallusto F., Lanzavecchia A. Exploring pathways for memory T cell generation. J. Clin. Invest. 108:2001;805
47. Peng L., Kjaergaard J., Plautz G.E., Awad M., Drazba J.A., Shu S., Cohen P.A. Tumor-induced L-selectin high suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. J. Immunol. 169:2002;4811
48. Hu H.M., Poehlein C.H., Urba W.J., Fox B.A. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res. 62:2002;3914